Institution
University of Missouri
Education•Columbia, Missouri, United States•
About: University of Missouri is a education organization based out in Columbia, Missouri, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 41427 authors who have published 83598 publications receiving 2911437 citations. The organization is also known as: Mizzou & Missouri-Columbia.
Topics: Population, Poison control, Health care, Gene, Mental health
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The Global Burden of Diseases, Injuries, and Risk Factors Study 2010 aimed to estimate annual deaths for the world and 21 regions between 1980 and 2010 for 235 causes, with uncertainty intervals (UIs), separately by age and sex, using the Cause of Death Ensemble model.
11,809 citations
••
TL;DR: This chapter discusses a wide variety of variables that proved instrumental in affecting the elaboration likelihood, and thus the route to persuasion, and outlines the two basic routes to persuasion.
Abstract: Publisher Summary
This chapter outlines the two basic routes to persuasion. One route is based on the thoughtful consideration of arguments central to the issue, whereas the other is based on the affective associations or simple inferences tied to peripheral cues in the persuasion context. This chapter discusses a wide variety of variables that proved instrumental in affecting the elaboration likelihood, and thus the route to persuasion. One of the basic postulates of the Elaboration Likelihood Model—that variables may affect persuasion by increasing or decreasing scrutiny of message arguments—has been highly useful in accounting for the effects of a seemingly diverse list of variables. The reviewers of the attitude change literature have been disappointed with the many conflicting effects observed, even for ostensibly simple variables. The Elaboration Likelihood Model (ELM) attempts to place these many conflicting results and theories under one conceptual umbrella by specifying the major processes underlying persuasion and indicating the way many of the traditionally studied variables and theories relate to these basic processes. The ELM may prove useful in providing a guiding set of postulates from which to interpret previous work and in suggesting new hypotheses to be explored in future research.
7,932 citations
••
University of Melbourne1, Stony Brook University2, City University of New York3, Princeton University4, University of Lausanne5, University of California, Berkeley6, University of Alaska Fairbanks7, National Institute of Water and Atmospheric Research8, Commonwealth Scientific and Industrial Research Organisation9, University of São Paulo10, University of Missouri11, Consejo Nacional de Ciencia y Tecnología12, University of Kansas13, Landcare Research14, AT&T15, McGill University16, James Cook University17, Swiss Federal Institute for Forest, Snow and Landscape Research18
TL;DR: This work compared 16 modelling methods over 226 species from 6 regions of the world, creating the most comprehensive set of model comparisons to date and found that presence-only data were effective for modelling species' distributions for many species and regions.
Abstract: Prediction of species' distributions is central to diverse applications in ecology, evolution and conservation science. There is increasing electronic access to vast sets of occurrence records in museums and herbaria, yet little effective guidance on how best to use this information in the context of numerous approaches for modelling distributions. To meet this need, we compared 16 modelling methods over 226 species from 6 regions of the world, creating the most comprehensive set of model comparisons to date. We used presence-only data to fit models, and independent presence-absence data to evaluate the predictions. Along with well-established modelling methods such as generalised additive models and GARP and BIOCLIM, we explored methods that either have been developed recently or have rarely been applied to modelling species' distributions. These include machine-learning methods and community models, both of which have features that may make them particularly well suited to noisy or sparse information, as is typical of species' occurrence data. Presence-only data were effective for modelling species' distributions for many species and regions. The novel methods consistently outperformed more established methods. The results of our analysis are promising for the use of data from museums and herbaria, especially as methods suited to the noise inherent in such data improve.
7,589 citations
••
TL;DR: A revised and updated classification for the families of the flowering plants is provided in this paper, which includes Austrobaileyales, Canellales, Gunnerales, Crossosomatales and Celastrales.
7,299 citations
••
Duke University1, Boston University2, Bristol-Myers Squibb3, Lenox Hill Hospital4, Oslo University Hospital5, University of California, San Francisco6, University of Alberta7, University of Missouri8, University of New Mexico9, Mayo Clinic10, Tokai University11, Goethe University Frankfurt12, University of Adelaide13, Charles University in Prague14, Autonomous University of Madrid15, St. John's Medical College16, Uppsala University17
TL;DR: In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality.
Abstract: A b s t r ac t Background Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin. Methods In this randomized, double-blind trial, we compared apixaban (at a dose of 5 mg twice daily) with warfarin (target international normalized ratio, 2.0 to 3.0) in 18,201 patients with atrial fibrillation and at least one additional risk factor for stroke. The primary outcome was ischemic or hemorrhagic stroke or systemic em - bolism. The trial was designed to test for noninferiority, with key secondary objec - tives of testing for superiority with respect to the primary outcome and to the rates of major bleeding and death from any cause. Results The median duration of follow-up was 1.8 years. The rate of the primary outcome was 1.27% per year in the apixaban group, as compared with 1.60% per year in the war - farin group (hazard ratio with apixaban, 0.79; 95% confidence interval (CI), 0.66 to 0.95; P<0.001 for noninferiority; P = 0.01 for superiority). The rate of major bleeding was 2.13% per year in the apixaban group, as compared with 3.09% per year in the warfarin group (hazard ratio, 0.69; 95% CI, 0.60 to 0.80; P<0.001), and the rates of death from any cause were 3.52% and 3.94%, respectively (hazard ratio, 0.89; 95% CI, 0.80 to 0.99; P = 0.047). The rate of hemorrhagic stroke was 0.24% per year in the apixaban group, as compared with 0.47% per year in the warfarin group (hazard ra - tio, 0.51; 95% CI, 0.35 to 0.75; P<0.001), and the rate of ischemic or uncertain type of stroke was 0.97% per year in the apixaban group and 1.05% per year in the warfarin group (hazard ratio, 0.92; 95% CI, 0.74 to 1.13; P = 0.42). Conclusions In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality. (Funded by Bristol-Myers Squibb and Pfizer; ARISTOTLE ClinicalTrials.gov number, NCT00412984.)
7,154 citations
Authors
Showing all 41750 results
Name | H-index | Papers | Citations |
---|---|---|---|
Michael Camilleri | 125 | 1084 | 58867 |
Omar K. Farha | 123 | 618 | 63896 |
Pamela S. Soltis | 120 | 543 | 61080 |
John A. Tainer | 119 | 493 | 48069 |
Lars Arendt-Nielsen | 118 | 1410 | 59474 |
Richard E. Petty | 118 | 452 | 80806 |
Angus C. Nairn | 118 | 469 | 44330 |
Mark A. Tarnopolsky | 115 | 644 | 42501 |
Kenneth H. Mayer | 115 | 1351 | 64698 |
Jizhong Zhou | 115 | 766 | 48708 |
Thomas E. Joiner | 114 | 775 | 54305 |
Paul Turner | 114 | 1099 | 61390 |
Andrew C. Heath | 113 | 503 | 41702 |
Keith D. Lillemoe | 112 | 658 | 50397 |
Robert L. Goldenberg | 111 | 712 | 48398 |